Summary
Medtronic plc's fiscal year 2016 10-K filing highlights a transformative year primarily driven by the $50 billion acquisition of Covidien plc, which closed in January 2015. This strategic move significantly expanded Medtronic's global reach and product portfolio, integrating Covidien's operations into its existing structure. The company organized into four primary operating segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group, with combined net sales reflecting the significant impact of the Covidien integration. Despite currency headwinds and the costs associated with integration, Medtronic demonstrated revenue growth across most segments. The company continues to invest heavily in research and development to drive therapy innovation and maintain market leadership in a competitive landscape. Management's focus remains on executing its strategies for therapy innovation, globalization, and economic value creation, aiming to enhance patient outcomes and improve healthcare efficiencies.
Financial Highlights
55 data points| Revenue | $28.83B |
| Cost of Revenue | $9.14B |
| Gross Profit | $19.69B |
| SG&A Expenses | $9.47B |
| Operating Income | $5.36B |
| Interest Expense | $1.39B |
| Net Income | $3.54B |
| EPS (Basic) | $2.51 |
| EPS (Diluted) | $2.48 |
| Shares Outstanding (Basic) | 1.41B |
| Shares Outstanding (Diluted) | 1.43B |
Key Highlights
- 1Completion of the $50 billion acquisition of Covidien plc in January 2015, significantly expanding Medtronic's scale and product offerings.
- 2Reorganization into four operating segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
- 3Net sales grew to $28.83 billion in fiscal year 2016, a 42% increase compared to fiscal year 2015, largely due to the inclusion of Covidien's results.
- 4Investment in Research and Development remained substantial, totaling $2.2 billion (7.7% of net sales) in fiscal year 2016, underscoring a commitment to innovation.
- 5Strong performance in the Cardiac and Vascular Group, showing a 9% increase in net sales, driven by growth across its divisions.
- 6The Minimally Invasive Therapies Group, significantly bolstered by the Covidien acquisition, reported $9.6 billion in net sales.
- 7The company continued to execute its share repurchase program, demonstrating a commitment to returning capital to shareholders.